Check out our most popular compounded medications! Get Started
Our Quinidine Sulfate 200 mg Slow Release (MEM4) Oral Capsules are expertly crafted to provide a steady release of quinidine sulfate, ensuring consistent therapeutic levels over an extended period. By incorporating Methocel E4M, a sophisticated controlled-release polymer, these capsules are engineered to dissolve slowly, minimizing the need for frequent dosing and enhancing patient adherence to treatment regimens. The use of Methocel E4M in our capsules allows for a controlled and prolonged release of quinidine sulfate, making it an ideal choice for patients requiring long-term arrhythmia control.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Quinidine Sulfate is an antiarrhythmic agent used to treat certain types of irregular heartbeats such as atrial fibrillation or ventricular arrhythmias. It works by restoring normal heart rhythm and maintaining a regular, steady heartbeat. Quinidine does this by blocking sodium channels and interfering with the electrical signals in the heart that can cause an irregular heartbeat. By stabilizing the heart's rhythm, quinidine sulfate can help to reduce symptoms such as palpitations, dizziness, and shortness of breath associated with arrhythmias.
The Quinidine Sulfate 200 mg Slow Release (MEM4) Oral Capsules are specially formulated with Methocel E4M, which is a type of hydrophilic polymer that swells and forms a gel when it comes into contact with gastric fluids. This gel matrix creates a barrier that controls the rate at which the quinidine sulfate is released from the capsule and absorbed into the bloodstream. The Methocel E4M polymer is designed to provide a slow and steady release of the drug over an extended period, which can help to maintain therapeutic levels of the medication in the body for a longer duration compared to immediate-release formulations.
This controlled-release mechanism offers several benefits for patients and prescribers. For patients, the slow release of quinidine sulfate means that the medication can be taken less frequently, which can improve adherence to the treatment regimen. Additionally, the sustained release of the drug can help to minimize fluctuations in blood levels, potentially reducing the risk of side effects and providing more consistent therapeutic effects. For prescribers, the slow-release formulation allows for more predictable pharmacokinetics and can simplify the dosing schedule, making it easier to manage patients with complex medication regimens.
It is important for patients to follow the prescribed dosing schedule and not to crush or chew the capsules, as this could disrupt the controlled-release mechanism and lead to the rapid release of the entire dose at once, increasing the risk of side effects. Patients should also be aware of potential drug interactions and side effects associated with quinidine sulfate, including but not limited to gastrointestinal disturbances, changes in vision, or signs of cinchonism, such as tinnitus, headache, and dizziness.
For prescribers considering this formulation for their patients, it is crucial to monitor patient response and adjust the dosage as necessary based on therapeutic goals and the presence of any side effects. Regular monitoring of electrocardiograms (ECGs) and serum quinidine levels may be necessary to ensure the safety and efficacy of the treatment.
If you have any questions or require further information about the Quinidine Sulfate 200 mg Slow Release (MEM4) Oral Capsules, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is dedicated to providing comprehensive support and guidance to ensure the best possible outcomes for your patients.
Quinidine sulfate is an antiarrhythmic agent used to treat certain types of irregular heartbeats. It works by affecting the action potential in the cardiac cells, thereby stabilizing the heart rhythm. When considering the use of quinidine sulfate 200 mg slow-release capsules, it is important to be aware of potential drug interactions that may affect the efficacy of the medication or increase the risk of adverse effects.
Quinidine can interact with a variety of medications, leading to either increased or decreased levels of quinidine in the blood. Drugs that inhibit the cytochrome P450 2D6 enzyme, such as fluoxetine and paroxetine, can increase quinidine levels and may enhance its effects and toxicity. Conversely, medications that induce this enzyme, like rifampin and phenobarbital, can decrease quinidine levels, potentially reducing its effectiveness.
Additionally, quinidine has the potential to interact with other cardiac medications. For instance, combining quinidine with digoxin can lead to increased digoxin levels, necessitating careful monitoring and possible dose adjustments. The use of quinidine with other antiarrhythmic drugs, such as amiodarone, can increase the risk of cardiac side effects, including QT prolongation, which can lead to a potentially life-threatening arrhythmia called torsades de pointes.
Quinidine may also interact with anticoagulants like warfarin, increasing the risk of bleeding. Patients on warfarin should have their international normalized ratio (INR) monitored closely when starting or stopping quinidine therapy. Furthermore, the concurrent use of quinidine with drugs that prolong the QT interval, such as certain antipsychotics and antibiotics, should be approached with caution due to the additive risk of QT prolongation.
It is also important to note that quinidine can affect blood glucose levels, and therefore, interactions with antidiabetic medications may require close monitoring of blood glucose and possible dose adjustments of the antidiabetic drug. Additionally, the acid-reducing medications, such as proton pump inhibitors and H2 antagonists, can alter the gastric pH, potentially affecting the release and absorption of quinidine from the Methocel E4M-based slow-release formulation.
Patients should be advised to avoid grapefruit juice and other grapefruit products, as they can increase quinidine serum concentrations, leading to toxicity. Alcohol should also be used with caution, as it may enhance the cardiovascular effects of quinidine.
Given the complexity of these interactions, it is crucial for prescribers to review the patient's complete medication profile, including over-the-counter drugs and herbal supplements, before initiating quinidine sulfate slow-release therapy. Adjustments to therapy and more frequent monitoring may be necessary to manage these interactions effectively. If you have any questions or require further clarification on drug interactions with quinidine sulfate slow-release capsules, please reach out to us at Bayview Pharmacy for professional advice and support.
The Quinidine Sulfate 200 mg Slow Release (MEM4) Oral Capsules are a specialized formulation designed to manage cardiac arrhythmias by providing a consistent therapeutic level of quinidine sulfate over an extended period. The key to this formulation's effectiveness lies in the use of Methocel E4M, a hydrophilic methylcellulose polymer that swells and forms a gel when it comes into contact with gastric fluids. This gel matrix creates a barrier through which the quinidine sulfate must diffuse to be released into the body.
As the capsule travels through the gastrointestinal tract, water is absorbed through the gel, causing the Methocel E4M to swell and gradually release the encapsulated quinidine sulfate. This controlled-release mechanism ensures a slow and steady absorption of the drug, maintaining a more uniform plasma concentration than that achieved with immediate-release formulations. By avoiding peaks and troughs in drug levels, the slow-release capsules can reduce the risk of side effects associated with high plasma concentrations and improve the efficacy of the drug during the dosing interval.
Quinidine sulfate is an antiarrhythmic agent used to treat certain types of irregular heartbeats, such as atrial fibrillation and ventricular arrhythmias. It works by blocking sodium channels and interfering with the electrical signals in the heart that can cause an irregular heartbeat. By stabilizing the heart's rhythm, quinidine sulfate can help to prevent serious complications such as stroke or sudden cardiac arrest. The slow-release formulation of quinidine sulfate is particularly beneficial for patients who require long-term management of their arrhythmias, as it provides a more consistent therapeutic effect and reduces the need for multiple daily doses, which can enhance patient adherence to the medication regimen.
It is important for both patients and prescribers to understand that the slow-release characteristics of this formulation are specifically engineered to match the pharmacokinetic profile of quinidine sulfate. The Methocel E4M polymer is carefully selected for its viscosity and hydrophilic properties to ensure that the release rate of the drug is appropriate for the intended dosing schedule. Patients should be advised not to crush or chew the capsules, as this would disrupt the controlled-release system and potentially lead to rapid drug release and increased side effects.
For prescribers considering this formulation for their patients, it is crucial to take into account the patient's overall health, including kidney and liver function, as these can affect the metabolism and excretion of quinidine sulfate. Additionally, patient-specific factors such as concomitant medications, comorbidities, and the specific type of arrhythmia being treated should be evaluated to determine the appropriateness of this slow-release formulation.
If you have any questions about the Quinidine Sulfate 200 mg Slow Release (MEM4) Oral Capsules or require further information on how this formulation can benefit your patients, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is dedicated to providing expert guidance and support to ensure the safe and appropriate use of our compounded medications.
This is a medication formulated with Quinidine Sulfate, an antiarrhythmic agent, encapsulated in a slow-release capsule. The formulation uses Methocel E4M as a controlled-release polymer designed to release the medication over an extended period for sustained therapeutic effects.
Methocel E4M is a type of hydrophilic polymer that forms a gel when it comes in contact with gastric fluids. This gel matrix controls the release of Quinidine Sulfate, allowing it to be released gradually into the bloodstream over an extended period.
A slow-release formulation reduces the frequency of dosing, which can improve patient compliance. It also provides more consistent blood levels of the medication, offering sustained therapeutic effects and potentially reducing the risk of side effects.
The dosing frequency will be determined by your healthcare provider based on your specific condition and response to therapy. Since this is a slow-release formulation, it may be prescribed less frequently than immediate-release forms.
No, you should not open, crush, or chew the capsules. Doing so can affect the slow-release properties of the medication, possibly resulting in too much of the drug being released at once.
Take the missed dose as soon as you remember. However, if it's close to the time of your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double up the dose to make up for the missed one.
Certain medications and foods may interact with Quinidine Sulfate, affecting how it works or increasing the risk of side effects. Discuss with your healthcare provider about any drugs you are taking and any dietary restrictions you should follow.
The potential side effects can include dizziness, nausea, vomiting, or stomach upset. More serious side effects require immediate medical attention such as changes in heartbeat, hearing problems, or allergic reactions. Always report any concerning symptoms to your healthcare provider.
These capsules should be stored at room temperature, away from light and moisture. Keep the medication out of reach of children and pets.
The safety of this medication for pregnant or breastfeeding women has not been fully established. It is essential to consult your healthcare provider before taking this medication if you are pregnant or nursing.
The safety and efficacy of Quinidine Sulfate Slow Release Capsules in pediatric patients have not been established. Use in children should be considered only when the benefits outweigh the risks and under the guidance of a healthcare professional.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
